Oxidized lipids and UV immunosuppression

氧化脂质和紫外线免疫抑制

基本信息

  • 批准号:
    7932683
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-10-01 至 2015-09-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): PROJECT SUMMARY: The primary goal of our research is to mechanistically characterize systemic immunosuppression induced by ultraviolet B radiation (UVB). The immunosuppressive effects of UVB are involved in the ability of this environmental stimulus to induce skin cancers. Moreover, UVB radiation treatments are used clinically to treat inflammatory skin disorders, in great part to its immunosuppressive effects. The planned research plans to take advantage of results of previous studies both in our laboratory and others indicating that UVB-mediated systemic immunosuppression involves novel glycerophosphocholine-derived lipids produced by epidermal cells in response to UVB. These compounds, some of which have not been structurally characterized, act as agonists for the Platelet-activating Factor (PAF) receptor. Accumulating evidence suggests that these PAF-R agonists exert immunosuppressive effects via a complex interplay of cell types and cytokines including mast cells, cyclooxygenase-2-produced eicosanoids, interleukin-10 and histamine. Two specific aims are planned to mechanistically characterize the complex pathway of UVB-mediated systemic immunosuppression using a well-established murine model of contact hypersensitivity. The first aim will use mass spectrometry to structurally characterize and quantitate PAF-R agonists produced by UVB in murine skin. The amounts of these novel PAF-R ligands produced enzymatically as well as through non- enzymatic free radical-mediated oxidation of glycerophosphosphocholines will be assessed using a mouse defective in PAF enzymatic synthesis and use of systemic antioxidants. The second aim will characterize the roles of mast cells and regulatory T cells using novel murine transplantation studies. Completion of the planned studies to characterize the cell types and mediators involved in UVB-mediated systemic immunosuppression should result in an enhanced understanding of this important process intimately involved in skin cancer. PUBLIC HEALTH RELEVANCE: PROJECT NARRATIVE: The primary goal of our research is to mechanistically characterize the cell types and mediators involved in ultraviolet B radiation (UVB)-mediated systemic immunosuppression. The immunosuppressive effects of UVB are involved in the ability of this environmental stimulus to induce skin cancers. These skin cancers and pre- cancerous actinic keratoses induced by chronic sun exposure are the most common form of neoplastic disorders found in veterans. Though usually not associated with increased mortality, actinic neoplasias constitute an enormous burden of health care resources and increased morbidity. Moreover, UVB radiation treatments are used clinically to treat inflammatory skin disorders, in great part to its immunosuppressive effects. These studies should result in an enhanced understanding of this important process.
描述(由申请人提供): 项目摘要:我们研究的主要目标是对紫外线B辐射(UVB)引起的全身性免疫抑制进行力学表征。UVB的免疫抑制作用与这种环境刺激诱发皮肤癌的能力有关。此外,UVB辐射疗法在临床上用于治疗炎症性皮肤病,这在很大程度上是因为它的免疫抑制作用。计划中的研究计划利用我们实验室和其他研究的结果,这些研究表明,UVB介导的全身免疫抑制涉及表皮细胞对UVB的反应产生的新型甘油磷胆碱衍生的脂类。这些化合物,其中一些还没有结构特征,作为血小板激活因子(PAF)受体的激动剂。越来越多的证据表明,这些PAF-R激动剂通过细胞类型和细胞因子(包括肥大细胞、环氧合酶-2产生的二十烷类化合物、白细胞介素10和组胺)的复杂相互作用而发挥免疫抑制作用。计划有两个特定的目标,利用一个公认的接触性超敏反应小鼠模型,从机械上表征UVB介导的全身免疫抑制的复杂途径。第一个目标是使用质谱仪对紫外线在小鼠皮肤中产生的PAF-R激动剂进行结构表征和定量。这些新的PAF-R配体的数量以及通过非酶自由基介导的甘油磷酸胆碱氧化产生的数量将使用PAF酶合成缺陷的小鼠和系统性抗氧化剂的使用进行评估。第二个目标将通过新的小鼠移植研究来表征肥大细胞和调节性T细胞的作用。完成计划中的研究,以确定UVB介导的全身免疫抑制所涉及的细胞类型和介质,应该会增强对这一与皮肤癌密切相关的重要过程的理解。 公共卫生相关性: 项目简介:我们研究的主要目标是从机制上描述紫外线B辐射(UVB)介导的全身免疫抑制所涉及的细胞类型和介体。UVB的免疫抑制作用与这种环境刺激诱发皮肤癌的能力有关。这些皮肤癌和癌前光化性角化病是退伍军人中发现的最常见的肿瘤性疾病。尽管光化性肿瘤通常与死亡率增加无关,但它构成了卫生保健资源的巨大负担和发病率的增加。此外,UVB辐射治疗在临床上用于治疗炎症性皮肤病,很大程度上是因为它的免疫抑制作用。这些研究应有助于加深对这一重要进程的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey B. Travers其他文献

Relevance of the Platelet-activating factor system in chemical warfare agents-induced effects
血小板活化因子系统在化学战剂诱导效应中的相关性
  • DOI:
    10.1016/j.freeradbiomed.2024.12.037
  • 发表时间:
    2025-02-16
  • 期刊:
  • 影响因子:
    8.200
  • 作者:
    Anita Thyagarajan;Jeffrey B. Travers;Ravi P. Sahu
  • 通讯作者:
    Ravi P. Sahu
Topical Photodynamic Therapy Generates Bioactive Microvesicle Particles: Evidence for a Pathway Involved in Immunosuppressive Effects
局部光动力疗法产生生物活性微泡颗粒:参与免疫抑制作用途径的证据
  • DOI:
    10.1016/j.jid.2022.12.018
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
    5.700
  • 作者:
    Oladayo A. Oyebanji;Chad Brewer;Sharlo Bayless;Benjamin Schmeusser;Danielle A. Corbin;Courtney E.W. Sulentic;Catherine M.T. Sherwin;Yanfang Chen;Christine M. Rapp;Elizabeth E. Cates;Yuhan Long;Jeffrey B. Travers;Craig A. Rohan
  • 通讯作者:
    Craig A. Rohan
Case Studies of Sustained Remission of Membranous Glomerulonephritis With Dupilumab Treatment
  • DOI:
    10.1016/j.ekir.2024.09.024
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mark H. Kaplan;Jessica M. Greco;Brad H. Rovin;Anthony M. Cannon;Abigail Pajulas;Jeffrey B. Travers;Ayman Hallab;Matthew J. Turner
  • 通讯作者:
    Matthew J. Turner
Toxic cutaneous responses from inhalant abuse
  • DOI:
    10.1016/j.jdcr.2018.10.009
  • 发表时间:
    2019-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ahmed Hawash;Jeffrey B. Travers;Sibel Gokce
  • 通讯作者:
    Sibel Gokce
Lymphocyte activation in the pathogenesis of psoriasis.
银屑病发病机制中的淋巴细胞活化。
  • DOI:
  • 发表时间:
    1997
  • 期刊:
  • 影响因子:
    6.5
  • 作者:
    David A. Norris;Jeffrey B. Travers;Donald Y.M. Leung
  • 通讯作者:
    Donald Y.M. Leung

Jeffrey B. Travers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey B. Travers', 18)}}的其他基金

Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
验证细观成像预测皮肤癌发生及其治疗反应
  • 批准号:
    10595503
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
验证细观成像预测皮肤癌发生及其治疗反应
  • 批准号:
    10295161
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
验证细观成像预测皮肤癌发生及其治疗反应
  • 批准号:
    10041690
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8967172
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8539867
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    8892803
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
IGF-1 and the initiation of non-melanoma skin cancer
IGF-1 与非黑色素瘤皮肤癌的发生
  • 批准号:
    9242476
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
The Indiana Cutaneous Biological Research Training Program
印第安纳州皮肤生物学研究培训计划
  • 批准号:
    8473519
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Oxidized lipids and UV immunosuppression
氧化脂质和紫外线免疫抑制
  • 批准号:
    8391609
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Oxidized lipids and UV immunosuppression
氧化脂质和紫外线免疫抑制
  • 批准号:
    8762399
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了